UNIPHAR PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.52 EUR | +0.40% |
|
-0.20% | -6.67% |
| Feb. 27 | Uniphar ups full-year dividend as profit falls but revenue climbs | AN |
| Feb. 27 | Uniphar Seeks M&A | CI |
| Sales 2024 * | 2.66B 2.84B | Sales 2025 * | 2.78B 2.98B | Capitalization | 688M 736M |
|---|---|---|---|---|---|
| Net income 2024 * | 50M 53.49M | Net income 2025 * | 55M 58.84M | EV / Sales 2024 * | 0.34 x |
| Net Debt 2024 * | 208M 222M | Net Debt 2025 * | 222M 238M | EV / Sales 2025 * | 0.33 x |
| P/E ratio 2024 * |
13.2
x | P/E ratio 2025 * |
12
x | Employees | 3,000 |
| Yield 2024 * |
0.76% | Yield 2025 * |
0.8% | Free-Float | 89.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Uniphar plc
More news
| 1 day | +0.40% | ||
| 1 week | -0.20% | ||
| Current month | -3.08% | ||
| 1 month | -5.97% | ||
| 3 months | -4.18% | ||
| 6 months | +20.00% | ||
| Current year | -6.67% |
1 week
2.49
2.68
1 month
2.492.90
Current year
2.443.00
1 year
1.983.44
3 years
1.985.08
5 years
0.975.08
10 years
0.975.08
| Managers | Title | Age | Since |
|---|---|---|---|
Gerard Rabbette
CEO | Chief Executive Officer | - | 10-02-28 |
Tim Dolphin
DFI | Director of Finance/CFO | 60 | 10-06-30 |
Allan Smylie
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Maurice Pratt
CHM | Chairman | - | 03-06-30 |
Tim Dolphin
DFI | Director of Finance/CFO | 60 | 10-06-30 |
Paul Hogan
BRD | Director/Board Member | 64 | 19-06-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2.52 | +0.40% | 63 416 |
| 24-04-25 | 2.51 | -3.83% | 255,987 |
| 24-04-24 | 2.61 | -2.06% | 124,708 |
| 24-04-23 | 2.665 | +1.72% | 241,431 |
| 24-04-22 | 2.62 | +3.76% | 759,520 |
Real-time Irish S.E., April 26, 2024 at 11:55 am EDT
More quotes
Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,800, the Group is active in Ireland, the United Kingdom, the Benelux, the Nordics, Germany and the United States.
The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar plc represents a strong combination of scale, growth and profitability.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.51
EUR
Average target price
4.25
EUR
Spread / Average Target
+69.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.67% | 734M | |
| +17.42% | 70.95B | |
| +5.38% | 8.67B | |
| +6.69% | 8.16B | |
| -20.96% | 7.91B | |
| +0.49% | 4.51B | |
| +17.12% | 4.31B | |
| -3.38% | 4.07B | |
| -2.61% | 3.84B | |
| +22.08% | 3.63B |
- Stock Market
- Equities
- UPR Stock
